Algert Global LLC Has $4.66 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Algert Global LLC grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 86.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,166 shares of the company’s stock after buying an additional 15,800 shares during the period. Algert Global LLC’s holdings in Neurocrine Biosciences were worth $4,664,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the fourth quarter worth approximately $25,000. Huntington National Bank raised its position in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company’s stock valued at $31,000 after buying an additional 97 shares in the last quarter. Brooklyn Investment Group lifted its holdings in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 115 shares during the period. GeoWealth Management LLC increased its stake in shares of Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after purchasing an additional 102 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its position in shares of Neurocrine Biosciences by 53.5% during the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company’s stock worth $51,000 after buying an additional 130 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Transactions at Neurocrine Biosciences

In other news, insider Julie Cooke sold 1,551 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.78, for a total value of $181,125.78. Following the transaction, the insider now owns 19,544 shares of the company’s stock, valued at approximately $2,282,348.32. The trade was a 7.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kevin Charles Gorman sold 5,844 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the sale, the director now owns 521,618 shares in the company, valued at $60,867,604.42. This represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,907 shares of company stock valued at $1,629,982. Insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on NBIX shares. Evercore ISI dropped their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th. Needham & Company LLC raised Neurocrine Biosciences from a “hold” rating to a “buy” rating and set a $138.00 price target for the company in a research note on Tuesday, April 15th. JPMorgan Chase & Co. raised their price objective on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 26th. Finally, Guggenheim decreased their target price on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Three analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $160.90.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $109.75 on Tuesday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.98. The business’s 50 day simple moving average is $106.03 and its two-hundred day simple moving average is $121.83. The stock has a market capitalization of $10.86 billion, a P/E ratio of 33.36, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.20 EPS. Sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences announced that its board has authorized a share repurchase plan on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.